20250825-交银国际证券-石药集团-01093.HK-2Q25仍承压但业绩拐点将至_研发_BD稳步推进_上调目标价_7页_382kb

报告摘要

Shiyao Group (1093 HK) Analysis Summary

Based on JPMorgan research report dated August 25, 2025, the analysis covers financial performance, future outlook, and valuation for Shiyao Group (1093 HK). Key findings include:

Current Price and Target: Current stock price is HKD 10.51. JPMorgan has updated the target price to HKD 9.30, representing an expected decrease of 11.6% from current levels. The rating remains neutral.
Performance and Outlook: Second-quarter 2025 results face pressure due to ongoing impacts from hospital and medical insurance cost controls, but there is potential for a performance recovery in the second half of 2025 and beyond. The company expects revenue and profit growth to resume double-digit rates by 2026-2027, driven by factors such as the fading of negative impacts, strong business development (BD) collaborations, and rebound in downstream businesses like原料药and功能食品.
Financial Highlights: JPMorgan revised earnings forecasts downward for 2025-2026 due to challenges from key products but projected stable gross margins around 68-69%. Adjustments in operating expenses are expected to improve efficiency. The dividend yield is notable, with a mid-year dividend of HKD 0.14 per share and an annualized expectation of at least HKD 0.28 per share.
Rating and Catalysts: Neutral rating maintained, with catalysts including successful progression of EGFR ADC drug development and potential BD deals. However, risks include lingering industry pressures and valuation considerations reflected in the price-adjusted target.
Valuation Summary: Using DCF model, the updated target price of HKD 9.30 implies a fair value based on 2026 financials, supporting overall neutrality.